PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation
Authors:
Open Access
- 28 December 2022
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 187, 106636
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81671945, 82203066)
This publication has 19 references indexed in Scilit:
- PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal CancerCellular Physiology and Biochemistry, 2017
- The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentinJournal of Cellular Physiology, 2017
- M2 macrophages induce EMT through the TGF‐β/Smad2 signaling pathwayCell Biology International, 2017
- Idiopathic pulmonary fibrosisThe Lancet, 2017
- USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cellsOncotarget, 2016
- Vimentin regulates activation of the NLRP3 inflammasomeNature Communications, 2015
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transitionThe FASEB Journal, 2010
- Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrixProceedings of the National Academy of Sciences, 2006